Ardelyx Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Ardelyx Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on Ardelyx, Maintains $10 Price Target
H.C. Wainwright Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Ed Arce maintains $Ardelyx(ARDX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 42.0% and a total
Wedbush Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $11
Wedbush analyst Laura Chico maintains $Ardelyx(ARDX.US)$ with a buy rating, and adjusts the target price from $15 to $11.According to TipRanks data, the analyst has a success rate of 49.4% and a
Wedbush Sticks to Its Buy Rating for Ardelyx (ARDX)
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet
Ardelyx (ARDX.US) sues USA CMS to oppose the bundling of payment system for Xphozah, a drug for kidney disease, into medical insurance.
Pharmaceutical company Ardelyx announced that it has filed lawsuits against the US Department of Health and Human Services and the Centers for Medicare & Medicaid Services (CMS) for medical insurance and medical subsidy services.
Citi Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $10
Citi analyst Yigal Nochomovitz maintains $Ardelyx(ARDX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 46.7% and a total
Ardelyx's Strategic Response to Regulatory Challenges: A High-Risk Buy Rating With Potential for Substantial Return
Recent 29% Pullback Isn't Enough to Hurt Long-term Ardelyx (NASDAQ:ARDX) Shareholders, They're Still up 108% Over 5 Years
The Ardelyx, Inc. (NASDAQ:ARDX) share price has had a bad week, falling 29%. But in stark contrast, the returns over the last half decade have impressed. In fact, the share price is 108% higher to
Ladenburg Thalmann Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $12.5
Ladenburg Thalmann analyst Matthew Kaplan maintains $Ardelyx(ARDX.US)$ with a buy rating, and adjusts the target price from $14.5 to $12.5.According to TipRanks data, the analyst has a success rate of
Ardelyx Is Maintained at Buy by Citigroup
Ardelyx Is Maintained at Buy by Citigroup
Ardelyx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 88.86% Citigroup $14 → $10 Maintains Buy 06/20/2024 — Cantor Fitzgerald Reiterates → Overweigh
TD Cowen Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $12
TD Cowen analyst Joseph Thome maintains $Ardelyx(ARDX.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 34.2% and a total aver
H.C. Wainwright Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $10
H.C. Wainwright analyst Ed Arce maintains $Ardelyx(ARDX.US)$ with a buy rating, and adjusts the target price from $13 to $10.According to TipRanks data, the analyst has a success rate of 39.2% and a t
Express News | Ardelyx, Inc. : H.c. Wainwright Cuts Target Price to $10 From $13
Citi Maintains Ardelyx(ARDX.US) With Buy Rating, Cuts Target Price to $10
Citi analyst Yigal Nochomovitz maintains $Ardelyx(ARDX.US)$ with a buy rating, and adjusts the target price from $14 to $10.According to TipRanks data, the analyst has a success rate of 40.7% and a to
Ardelyx's Tumble Seen as Opportunity To Buy Dip -- Market Talk
0818 ET - Tuesday's 30% sell-off in Ardelyx presents "a clear and justifiable opportunity to buy the stock," say analysts at Citi. In a research note, Citi says that while Ardelyx's Medicare/Medicaid
Express News | Ardelyx Inc : Raymond James Cuts Target Price to $15 From $16
Express News | Ardelyx Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $7 From $15